
Lower Complication Rates in Sludge vs Gallstone Pancreatitis
Patients with sludge- or microlithiasis-induced acute pancreatitis (AP) had significantly lower rates of pancreaticobiliary complications than those with gallstone-induced AP.
METHODOLOGY:
Researchers enrolled 789 patients who were hospitalised with their first episode of biliary pancreatitis between January 2018 and April 2020 at 16 Spanish and two Mexican centres.
Patients were divided into two groups on the basis of types of calculi: those with sludge- or microlithiasis-induced AP (n = 274; median age, 71.9 years; 53.2% women) and gallstone-induced AP (n = 515; median age, 68.9 years; 54.3% women), with neither group receiving cholecystectomy during admission.
The primary endpoint was the rate of pancreaticobiliary complications, measured as the complication-free survival rate, in patients with sludge- or microlithiasis-induced vs those with gallstone-induced AP.
The multivariate analysis was conducted to assess the effect of multiple variables on complication-free survival.
The median follow-up duration was 8.15 months for the sludge/microlithiasis AP cohort and 6.13 months for the gallstone AP cohort (P < .001).
TAKEAWAY:
Patients with gallstone-induced AP had a significantly higher rate of pancreaticobiliary complications than those with sludge- or microlithiasis-induced AP (41.75% vs 32.12%; P = .01).
Patients in the gallstone AP group had a significantly lower complication-free survival rate than those in the sludge/microlithiasis AP group (log-rank P = .0022).
The most frequent complication was recurrent AP, occurring in 24.08% of patients in the gallstone AP group and 20.07% of those in the sludge/microlithiasis AP group.
The medium Charlson Comorbidity Index was independently associated with a higher risk for pancreatobiliary complications for the sludge/microlithiasis AP cohort (hazard ratio [HR], 2.07; P = .005). In the gallstone AP group, older age was associated with a reduced risk for pancreaticobiliary complications (HR, 0.54; P < .001).
IN PRACTICE:
"The lower complication rate observed during follow-up supports, for the first time, the consideration of the sludge/microlithiasis AP cohort as a distinct clinical entity — one that may warrant a more conservative interventional approach, particularly in patients with elevated perioperative risk," the authors of the study wrote.
SOURCE:
This study was led by Simon Sirtl, MD, LMU University Hospital, Munich, Germany. It was published online on June 28, 2025, in Digestive and Liver Disease.
LIMITATIONS:
The study's retrospective design precluded prospective stratification depending on the newly published consensus definitions for biliary sludge and microlithiasis. The inability to stratify patients along with only 17.1% of patients undergoing endoscopic ultrasound introduced heterogeneity into the sludge/microlithiasis AP cohort as the classification remained examiner dependent. Furthermore, the sample size was calculated for pancreatobiliary complications in symptomatic cholelithiasis rather than specifically for AP.
DISCLOSURES:
The trial was funded by AEG Young Talent Grant 2021. One author reported receiving funding from the Deutsche Forschungsgemeinschaft (German Research Foundation) and the LMU Munich Clinician Scientist Program.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Versailles Hospital Center adopts digital pathology platform
The Versailles Hospital Center has begun a digital pathology transformation by selecting Tribun Health's CaloPix imaging platform. This move is a significant step in modernising the French public healthcare system's diagnostic services and integrating artificial intelligence (AI) into pathology. The implementation of CaloPix within the pathology department is set to streamline primary diagnostics and interdisciplinary collaboration. Tribun Health CEO Jean-François POMEROL said: 'This choice reflects a shared commitment to innovating for more effective, collaborative, and patient-centered healthcare.' Tribun Health's platform has a user-friendly interface and flexibility, catering to the dynamic requirements of hospital infrastructures. It is designed to be open and interoperable, allowing it to integrate with the hospital's digital strategy. This initiative is in line with the Versailles Hospital Center and GHT 78 Sud's digital objectives, which are coordinated with GHT Nord. It contributes to a national effort to upgrade and digitise healthcare facilities. Versailles Hospital Center is GHT 78 Sud's supporting institution. Versailles Hospital Center Pathology Department head Dr Claire GLASER said: 'The selection of CaloPix is fully aligned with our digital transformation strategy. We were impressed by the solution's user-friendliness, performance, and the quality of support offered by Tribun Health's teams. 'This project, developed in collaboration with the GHT Yvelines Nord, marks a key step for the future of our specialty in the region, particularly regarding AI and collaborative work. It also enhances our integration into APHP's expert networks equipped with the same software.' Tribun Health uses data-driven technology and AI to improve precision and minimise turnaround times to assist laboratories and hospitals in transitioning from glass slide pathology to complete digital solutions. "Versailles Hospital Center adopts digital pathology platform" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
an hour ago
- Yahoo
Plans for new hospital in city to meet high demand
Plans have been submitted by a developer to build a new city hospital for day patients to tackle a "continued increase" in waiting times. Thorpe Wood Hospital in Peterborough would be part of the private hospital group, Ramsay Health Care UK, which already runs the Fitzwilliam Hospital in the city. In a report submitted to Peterborough City Council, developers ELG said the project would help to manage "excessive demand in the local health system". It said the Fitzwilliam had already "reached capacity", adding: "Essential expansion is urgently required for day case and community diagnostics." It said: "This investment is seen as being important and intrinsic to reducing the continued increase in patient waiting times and deferred treatment and diagnostic services in the community." There would be on-site magnetic resonance imaging (MRI) facilities and computed tomography (CT) scanners for early diagnostic and surgical intervention. This would allow the Fitzwilliam to have more bed capacity for procedures such as complex surgeries. The new facility would be dedicated to several different areas including general surgery, ophthalmology, urology and gynaecology. The report said there was a "huge task" of clearing a backlog of NHS patients waiting for treatment, which has led to private hospitals taking on the care of some NHS patients. It is estimated 142 members of staff would work at the hospital, caring for patients coming via the private sector as well as the NHS. The single-storey hospital building is planned for a business park on the western edge of Peterborough. The plans have yet to be considered by Peterborough City Council. Follow Peterborough news on BBC Sounds, Facebook, Instagram and X. Plan to convert church hall into homes submitted Safety measures to be introduced at busy junction Former reptile pet shop to become pizza takeaway Peterborough City Council Planning Register
Yahoo
an hour ago
- Yahoo
UnitedHealth Under Fire as Medicaid & Centene Bombshell Rattle Sector
UnitedHealth Group Incorporated UNH continues to face challenges amid a turbulent healthcare insurance landscape. The passage of the 'One Big Beautiful Bill Act' through Congress, ready for President Donald Trump's signature, threatens to significantly reduce federal Medicaid spending. According to reports, approximately 11.8 million Americans are expected to lose Medicaid coverage by 2034, with 5.2 million affected by new work requirements alone. To curb state-level Medicaid expenditures, the bill gradually limits the use of 'provider taxes' as a revenue source. However, it also allocates $50 billion in funding to support rural hospitals impacted by these cuts. While insurers like UnitedHealth and Humana Inc. HUM may encounter short-term pressure from shrinking Medicaid rolls, they could ultimately benefit as displaced members shift toward private coverage options. UnitedHealth's Medicaid membership declined 4% in 2023, 5.2% in 2024, and 1.4% in the first quarter of 2025. The proposed elimination of ACA marketplace tax credits will likely propel more people into employer-sponsored plans. Meanwhile, Medicare Advantage may gain traction, as seniors grapple with increased out-of-pocket expenses due to rollbacks in Medicare Savings Programs. UnitedHealth's Medicare Advantage enrollment rose by 8.3% in 2023, 1.9% in 2024, and 6.3% in the first quarter of 2025. Another major development shook the market as Centene Corporation CNC, a major Medicaid player, withdrew its 2025 earnings guidance late Tuesday, citing unexpected enrollment shifts and higher medical costs. The move, mirroring UnitedHealth's earlier decision, rattled the managed care sector. Centene shares witnessed massive declines following the news, and peers like UnitedHealth and Humana followed suit. Centene shares plummeted 41.2% following the announcement, dragging down peers: UnitedHealth and Humana dropped 5.4% and 5.1%, respectively, despite broader market gains driven by tech strength and encouraging jobs data. Image Source: Zacks Investment Research From a valuation standpoint, UnitedHealth trades at a forward price-to-earnings ratio of 12.99, up from the industry average of 11.49. UNH currently carries a Value Score of A. Image Source: Zacks Investment Research The Zacks Consensus Estimate for UnitedHealth's 2025 earnings is pegged at $22.07 per share, implying a 20.2% drop from the year-ago period. Image Source: Zacks Investment Research The stock currently carries a Zacks Rank #5 (Strong Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH) : Free Stock Analysis Report Humana Inc. (HUM) : Free Stock Analysis Report Centene Corporation (CNC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio